Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals, Inc. to 3.55%

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, reporting a 3.55% ownership stake in Apellis Pharmaceuticals, Inc. (APLS). As of the event date of March 31, 2026, the reporting persons beneficially owned 4,532,374 shares of Common Stock. This position represents an increase from a previously reported 0.0% ownership, indicating a new significant holding for the investment adviser and its affiliates. The filing indicates that the shares are held with shared voting and dispositive power. David Kroin, as the Managing Member of the General Partner of Deep Track Capital and Director of the Master Fund, may be considered a control person for the purposes of this filing. The securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The calculation of ownership is based on 127,829,909 shares of Common Stock outstanding as of February 17, 2026.